Selpercatinib Dosing Guide: Weight-Based Precision Targeting for RET-Driven Tumors

　　Selpercatinib(brand name Retevmo)is an oral,highly selective RET kinase inhibitor and the first RET-targeted therapy to receive regulatory approval worldwide.Unlike conventional chemotherapy or multi-target tyrosine kinase inhibitors,selpercatinib was specifically engineered to inhibit RET fusion proteins and mutant RET kinases with high potency while maintaining selectivity against other kinases,thereby maximizing anti-tumor efficacy and minimizing off-target toxicity.The drug also demonstrates favorable central nervous system penetration,offering therapeutic potential for patients with brain metastases.

　　Dosing is stratified by body weight and administered twice daily.According to the prescribing information,selpercatinib dosing is not uniform but is determined by patient weight.For patients weighing less than 50 kilograms,the recommended dose is 120 mg taken orally twice daily.For patients weighing 50 kilograms or more,the recommended dose is 160 mg taken orally twice daily.The two daily doses should be taken approximately 12 hours apart,ideally at consistent times each day to maintain stable plasma concentrations.The tablets may be taken with or without food and should be swallowed whole without chewing,crushing,or splitting.Treatment continues until disease progression or unacceptable toxicity.

　　Dose modifications must follow established guidelines.If adverse reactions occur during therapy,the treating physician may recommend dose reduction or temporary interruption in accordance with the prescribing information,with subsequent adjustments based on recovery status.For patients under 50 kg,the dose is typically reduced in a stepwise manner from 120 mg twice daily;for those at or above 50 kg,reductions proceed from 160 mg twice daily.Patients should never adjust their dose or dosing frequency independently—all modifications must be made under the guidance of a qualified healthcare professional.

　　RET molecular testing is mandatory before initiating therapy.Selpercatinib is not indicated for all lung cancer or thyroid cancer patients.Its use requires confirmed RET gene abnormalities.Specifically,for non-small cell lung cancer and differentiated thyroid cancer,validated testing must confirm the presence of a RET gene fusion in tumor tissue.For medullary thyroid cancer,a pathogenic RET gene mutation must be identified.Molecular testing may be performed on tumor tissue specimens,and in cases where tissue acquisition is challenging,liquid biopsy may serve as a complementary approach.Only when the molecular target is clearly established can eligibility for selpercatinib therapy be determined.

　　Indications span multiple RET-driven malignancies.Current core indications include:adults with locally advanced or metastatic RET fusion-positive NSCLC;patients with advanced or metastatic RET-mutant medullary thyroid cancer requiring systemic therapy,including those who have progressed on prior multi-kinase inhibitors;and patients with RET fusion-positive radioactive iodine-refractory differentiated thyroid cancer.Selpercatinib is also approved for advanced or metastatic solid tumors harboring RET gene fusions in patients who have progressed on prior treatment and lack satisfactory alternative options.Notably,results from the LIBRETTO-432 trial announced in 2026 demonstrated that selpercatinib as adjuvant therapy following surgery for early-stage(IB–IIIA)RET fusion-positive NSCLC significantly reduces the risk of disease recurrence or death,further expanding its clinical utility.

　　Practical administration considerations.Patients should maintain a consistent dosing schedule and avoid missed doses.If a dose is forgotten and the next scheduled dose is more than 6 hours away,the missed dose should be taken as soon as possible.If less than 6 hours remain before the next dose,the missed dose should be skipped and the regular schedule resumed—patients should never take a double dose to compensate.During treatment,periodic monitoring of complete blood counts,hepatic function,electrolytes,blood pressure,and electrocardiogram is essential to detect and manage potential adverse events such as elevated liver enzymes,hypertension,QT prolongation,hemorrhage,or hypersensitivity reactions.Patients of reproductive potential should use effective contraception during treatment and for a specified period after discontinuation.

　　In summary,the standard selpercatinib regimen is directly tied to body weight:120 mg twice daily for patients under 50 kg and 160 mg twice daily for those at or above 50 kg.Accurate identification of RET gene abnormalities,adherence to standardized dosing protocols,and regular monitoring constitute the three pillars ensuring both efficacy and safety of selpercatinib therapy.